LENZ Therapeutics, Inc. Common Stock (LENZ) Stock
NASDAQ · LENZ
3.90
Fundamentals
Market cap
$123.01M
Price / Earnings ratio
-0.9x
Price / Sales ratio
5.4x
Price / Book ratio
0.5x
Return on assets
-43.0%
Ex-Dividend date
22 Mar 2024
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

MarketBeat
LENZ Therapeutics Q2 Earnings Call Highlights
NeutralLENZAugust 11, 2026
MarketBeatNeutral
LENZ Therapeutics Q2 Earnings Call Highlights
LENZ

Zacks Investment Research
LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss, Beats Revenue Estimates
NeutralLENZAugust 11, 2026
Zacks Investment ResearchNeutral
LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss, Beats Revenue Estimates
LENZ

Zacks Investment Research
Earnings Preview: LENZ Therapeutics, Inc. (LENZ) Q2 Earnings Expected to Decline
NeutralLENZJuly 22, 2026
Zacks Investment ResearchNeutral
Earnings Preview: LENZ Therapeutics, Inc. (LENZ) Q2 Earnings Expected to Decline
LENZ

Proactive Investors
LENZ Therapeutics adds China partner for presbyopia drug VIZZ
NeutralLENZJune 8, 2026
Proactive InvestorsNeutral
LENZ Therapeutics adds China partner for presbyopia drug VIZZ
LENZ
Technicals
OscillatorsStrong Sell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral1
Buy1
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
23M15M8M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
367M242M121M0
Revenue to Profit
2025$19.1M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-82.1M
Net incomeEarnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

MarketBeat
LENZ Therapeutics Q2 Earnings Call Highlights
NeutralLENZAugust 11, 2026
MarketBeatNeutral
LENZ Therapeutics Q2 Earnings Call Highlights
LENZ

Zacks Investment Research
LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss, Beats Revenue Estimates
NeutralLENZAugust 11, 2026
Zacks Investment ResearchNeutral
LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss, Beats Revenue Estimates
LENZ

Zacks Investment Research
Earnings Preview: LENZ Therapeutics, Inc. (LENZ) Q2 Earnings Expected to Decline
NeutralLENZJuly 22, 2026
Zacks Investment ResearchNeutral
Earnings Preview: LENZ Therapeutics, Inc. (LENZ) Q2 Earnings Expected to Decline
LENZ

Proactive Investors
LENZ Therapeutics adds China partner for presbyopia drug VIZZ
NeutralLENZJune 8, 2026
Proactive InvestorsNeutral
LENZ Therapeutics adds China partner for presbyopia drug VIZZ
LENZ

MarketBeat
LENZ Therapeutics Q1 Earnings Call Highlights
NeutralLENZMay 12, 2026
MarketBeatNeutral
LENZ Therapeutics Q1 Earnings Call Highlights
LENZ

Zacks Investment Research
LENZ Therapeutics, Inc. (LENZ) Reports Q1 Loss, Beats Revenue Estimates
NeutralLENZMay 11, 2026
Zacks Investment ResearchNeutral
LENZ Therapeutics, Inc. (LENZ) Reports Q1 Loss, Beats Revenue Estimates
LENZ

The Motley Fool
Why Lenz Therapeutics Stock Plummeted by Almost 20% This Week
NeutralLENZMarch 27, 2026
The Motley FoolNeutral
Why Lenz Therapeutics Stock Plummeted by Almost 20% This Week
LENZ

The Motley Fool
Why Lenz Therapeutics Stock Crashed Today
NeutralLENZMarch 24, 2026
The Motley FoolNeutral
Why Lenz Therapeutics Stock Crashed Today
LENZ

Zacks Investment Research
LENZ Therapeutics, Inc. (LENZ) Reports Q4 Loss, Misses Revenue Estimates
NeutralLENZMarch 24, 2026
Zacks Investment ResearchNeutral
LENZ Therapeutics, Inc. (LENZ) Reports Q4 Loss, Misses Revenue Estimates
LENZ

24/7 Wall Street
Huge Insider Buying From Buffett, an NFL Team Owner, a New CEO
NeutralLENZMarch 31, 2024
24/7 Wall StreetNeutral
Huge Insider Buying From Buffett, an NFL Team Owner, a New CEO
LENZ
About LENZ Therapeutics, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees152
CEOMr. Evert B. Schimmelpennink
IPO DateJun 24, 2021
HeadquartersSolana Beach, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Evert B. Schimmelpennink | President, CEO, Secretary & Director | 1972 |
| Mr. James W. McCollum | Co-Founder & Director | 1955 |
| Mr. Shawn Olsson | Chief Commercial Officer | 1983 |
| Mr. Marc G. Odrich M.D. | Chief Medical Officer | 1959 |
| Mr. Daniel R. Chevallard CPA | Chief Financial Officer | 1980 |
| Mr. Domenick Porfidia | Vice President of Sales | — |
| Mr. David Choromanski | Vice President of Marketing | — |
| Ms. Melissa Rosness | Senior Vice President of Manufacturing Operations | — |
| Kris Gambelin | Senior Vice President of Regulatory & Clincal Operations | — |
Fundamentals
Valuation
Market cap$123.01M
Price-to-sales ratio5.44
Price-to-book value0.53
Price-earnings ratio-0.90
Return on Equity-47.00%
Return on Sales-517.00%
Return on Assets-43.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-4.13
Income Statement
Average volume716,055
EBITDA$-108.13M
1 year high (52w)$50.40
1 year low (52w)$3.60
Dividend
Ex dividend date22 Mar 2024
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsStrong Sell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
2 Wall Street Analyst Ratings
HOLD
50% Buy
50% Hold
0% Sell
Target price
$22.50
Est return
473.98%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | +37.8 | -24.5 | -3.3 | +14.7 | +40.4 | -5.0 | +4.5 | +18.2 | +27.5 | -22.7 | ||
| 2025 | -9.8 | -14.0 | +19.4 | +9.7 | +1.1 | +0.5 | -0.9 | +28.9 | +18.7 | -39.4 | +9.3 | -47.4 |
| 2026 | -1.1 | -17.2 | -33.1 | -4.0 | -12.4 | -23.7 | -8.5 | +4.2 | -25.0 |



